CRIS Current Research Information System

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.637
EU - Europa 1.584
AS - Asia 938
AF - Africa 112
SA - Sud America 8
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.626
GB - Regno Unito 459
SE - Svezia 325
VN - Vietnam 293
CN - Cina 292
SG - Singapore 214
IT - Italia 199
DE - Germania 196
IN - India 93
IE - Irlanda 80
FR - Francia 67
RU - Federazione Russa 62
EE - Estonia 38
ZA - Sudafrica 35
TG - Togo 33
UA - Ucraina 32
CH - Svizzera 28
BG - Bulgaria 25
CI - Costa d'Avorio 25
FI - Finlandia 22
BE - Belgio 21
JO - Giordania 17
NG - Nigeria 13
CA - Canada 10
GR - Grecia 9
IR - Iran 7
NL - Olanda 6
HK - Hong Kong 5
TR - Turchia 5
AT - Austria 4
AU - Australia 4
BR - Brasile 4
ID - Indonesia 3
CZ - Repubblica Ceca 2
EG - Egitto 2
LT - Lituania 2
MA - Marocco 2
PL - Polonia 2
SC - Seychelles 2
TW - Taiwan 2
AR - Argentina 1
CO - Colombia 1
DK - Danimarca 1
ES - Italia 1
EU - Europa 1
JP - Giappone 1
KR - Corea 1
LB - Libano 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 5.285
Salva come PNG Salva come JPEG
Città #
Southend 416
Fairfield 397
Chandler 253
Dong Ket 205
Ashburn 203
Singapore 188
Seattle 182
Woodbridge 168
Houston 161
Cambridge 156
Wilmington 142
Ann Arbor 137
Princeton 92
Dublin 80
Santa Clara 80
Boardman 53
Nanjing 44
Westminster 42
Padova 37
Bologna 36
Lomé 33
Bremen 32
Jinan 31
Abidjan 25
Berlin 25
Bern 25
Sofia 25
New York 23
Shenyang 23
Beijing 22
Helsinki 22
Brussels 21
Saint Petersburg 20
Amman 17
Milan 16
San Diego 16
Turin 16
Abeokuta 13
Falls Church 13
Hyderabad 11
Jacksonville 11
Changsha 10
Dearborn 10
Hebei 10
Zhengzhou 10
Tianjin 9
Guangzhou 8
London 8
Los Angeles 8
Nanchang 8
Norwalk 8
Redmond 8
Chicago 7
Florence 7
Hangzhou 7
Hefei 7
Olalla 7
Paris 7
Redwood City 7
Frankfurt am Main 6
Fremont 6
Columbus 5
Des Moines 5
Haikou 5
Istanbul 5
Munich 5
Ningbo 5
Taiyuan 5
Farra d'Isonzo 4
Harbin 4
Jiaxing 4
Kunming 4
Medford 4
Mountain View 4
Phoenix 4
Plauen 4
Shanghai 4
Wenzhou 4
Bühl 3
Caprino Veronese 3
Ferrara 3
Fuzhou 3
Gloucester 3
Jakarta 3
Kingwood 3
Lanzhou 3
Leawood 3
North York 3
Piacenza 3
Riva 3
Rome 3
San Francisco 3
Toronto 3
Vienna 3
Wayne 3
Winnipeg 3
Xi'an 3
Amherst Junction 2
Amsterdam 2
Andover 2
Totale 3.808
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 200
A case report of acute myeloid leukemia and neurofibromatosis 1 178
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 174
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 169
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 162
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 161
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 160
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 156
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 150
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 145
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 145
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 143
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 143
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 129
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 129
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 128
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 128
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 128
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 126
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 125
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 119
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 118
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 112
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 111
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 110
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 108
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 107
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 101
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 98
null 98
null 96
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 93
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 92
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 91
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors 87
The CD47 pathway is deregulated in human immune thrombocytopenia 86
null 86
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 85
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 85
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 79
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 69
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 64
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 40
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 40
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 30
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 26
Totale 5.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020819 0 0 0 0 0 0 192 193 195 106 67 66
2020/2021803 130 44 11 17 36 19 23 37 77 51 32 326
2021/2022945 75 36 45 113 87 47 29 46 39 114 169 145
2022/20231.027 109 164 63 144 54 81 31 63 176 42 53 47
2023/2024246 14 42 28 29 20 58 4 10 6 16 8 11
2024/2025544 46 166 82 84 122 37 7 0 0 0 0 0
Totale 5.428